| Stereochemistry | UNKNOWN |
| Molecular Formula | C28H33N5O2S |
| Molecular Weight | 503.659 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C(N(CCCN)C(=O)C1=CC=C(C)C=C1)C2=NC3=C(C(C)=NS3)C(=O)N2CC4=CC=CC=C4
InChI
InChIKey=SMFXSYMLJDHGIE-UHFFFAOYSA-N
InChI=1S/C28H33N5O2S/c1-18(2)24(32(16-8-15-29)27(34)22-13-11-19(3)12-14-22)25-30-26-23(20(4)31-36-26)28(35)33(25)17-21-9-6-5-7-10-21/h5-7,9-14,18,24H,8,15-17,29H2,1-4H3
AZD4877 was developed by AstraZeneca as a potent inhibitor of the mitotic spindle kinesin, Eg5. AZD4877 participated in clinical trials phase I/II for patients with acute myeloid leukemia, the study was terminated due to lack of efficacy. In addition, the drug was studied in Phase II in patients with previously treated advanced urothelial cancer. However, limited clinical efficacy stops the further development of AZD4877 in urothelial cancer.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
PubMed
Patents
ACTIVE MOIETY
